Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Russell Greig Leaves GSK's SR One

This article was originally published in The Pink Sheet Daily

Executive Summary

The managing partner and president of GSK's corporate venture group appears to have quietly moved on.

You may also be interested in...



In Advance Of HSV-2 Vaccine Trials, Genocea Taps Investors For $35 Million

The four-year-old antigen discovery platform developer has added corporate VCs, seeking to broaden its eventual exit opportunities.

In Advance Of HSV-2 Vaccine Trials, Genocea Taps Investors For $35 Million

The four-year-old antigen discovery platform developer has added corporate VCs, seeking to broaden its eventual exit opportunities.

Venture Data Continues To Haunt The Biotech Landscape

Venture firms suffered fundraising woes last year, and a handful of biopharma funds stopped investing. It could get worse.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel